Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.62 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.62 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | IL1B | P01584 | 1/20 | 0.62 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.57 |
| ▸ | AXL | P30530 | 6/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438142 | 1.00 | CRBN (0.62) | CRBNIKZF3DDB1IKZF1BRD4 | |
| Hydrochloric Acid SCHEMBL30772822 | 0.99 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL21814682 | 0.99 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL22636509 | 0.99 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL27347582 | 0.99 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL24142000 | 0.99 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19747349 | 0.99 | CRBN (0.61) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL21596986 | 0.97 | CRBN (0.63) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL30438018 | 0.97 | CRBN (0.63) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL23093113 | 0.93 | CRBN (0.65) | CRBNIKZF3DDB1IKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | claimed |
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3440066-B1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11192898-B2 | MDM2 protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192898-B2 | MDM2 protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3440082-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | The Regents of The University of Michigan (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440066-A1 | MDM2 PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017180417-A1 | BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | CRBN 45/4885IKZF3 617/4885DDB1 161/4885 |
| US-11192898-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | CRBN 605/4885IKZF3 555/4885DDB1 68/4885 |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | CRBN 151/4885IKZF3 231/4885DDB1 313/4885 |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | CRBN 605/4885IKZF3 555/4885DDB1 68/4885 |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | CRBN 151/4885IKZF3 231/4885DDB1 313/4885 |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | CRBN 605/4885IKZF3 555/4885DDB1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.